Browse Prior Art Database

A crystalline form of (4R,12aS)-7-(benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl- 6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1- b][1,3]oxazine-9-carboxamide

IP.com Disclosure Number: IPCOM000237544D
Publication Date: 2014-Jun-23
Document File: 2 page(s) / 20K

Publishing Venue

The IP.com Prior Art Database

This text was extracted from a PDF file.
This is the abbreviated version, containing approximately 67% of the total text.

Page 01 of 2

A crystalline form of (4R,12aS)-7-(benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl- 6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-
b][1,3]oxazine-9-carboxamide

     Provided herein is a process for preparing a crystalline form of (4R,12aS)-7- (benzyloxy)-N-(2,4-difluorobenzyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro- 2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, referred herein as Compound I. The process is described in Example 1. The isolated samples were analyzed by X-ray powder diffraction ("XRPD"), which indicated a formation of a crystalline form of Compound I. Figure 1 depicts the XRPD of the obtained crystalline form.

    Compound I may be used for preparing (4R,12aS)-9-((2,4- difluorobenzyl)carbamoyl)-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H- pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and salts thereof.

Figure 1: XRPD of a crystalline form of Compound I

Degrees two-theta


According to Figure 1, the crystalline form of Compound I is characterized by XRPD peaks at: 8.1, 8.6, 9.5, 11.0, 12.1, 14.9, 16.6, 17.2, 17.9 and 23.5 degrees 2- theta ± 0.2 degrees 2-theta.


Page 02 of 2

XRPD method:

    The analysis was performed on ARL (SCINTAG) powder X-Ray diffractometer model X'TRA equipped with a solid state detector. Copper radiation of
1.5418 Å was used. Scanning parameters: range: 2-40 degrees two-theta; scan mode: continuous scan; step size: 0.05°, and a rate of 3 deg/min.

Example 1: A process for preparing a crystallin...